The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence:: Preclinical evidence

被引：43

作者：

Colombo, Giancarlo

Orru, Alessandro

Lai, Paola

Cabras, Claudia

Maccioni, Paola

Rubio, Marina

Gessa, Gian Luigi

Carai, Mauro A. M.

机构：

[1] CNR, Inst Neurosci, I-00185 Rome, Italy

[2] Univ Cagliari, Dept Neurosci, Cagliari, Italy

[3] Univ Complutense, Dept Biochem & Mol Biol, E-28040 Madrid, Spain

来源：

MOLECULAR NEUROBIOLOGY | 2007年 / 36卷 / 01期

关键词：

cannabinoid CB1 receptor antagonist; rimonabant; alcohol; alcohol dependence (alcoholism); alcohol drinking and seeking behavior; animal models of alcoholism;

D O I：

10.1007/s12035-007-0017-y

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Several lines of preclinical evidence indicate the ability of the prototypic cannabinoid CB1 receptor antagonist, rimonabant, to suppress various alcohol-related behaviors, including alcohol drinking and seeking behavior and alcohol self-administration in rats and mice. Together, these data-synthetically reviewed in the present paper-suggest (a) the involvement of the cannabinoid CB1 receptor in the neural substrate controlling alcohol intake, alcohol reinforcement, and the motivational properties of alcohol and (b) that rimonabant may constitute a new and potentially effective medication for the treatment of alcohol dependence.

引用

页码：102 / 112

页数：11

共 65 条

[1]

Anton RF, 2001, J CLIN PSYCHIAT, V62, P11

[2] Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors [J].